Bicara Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Bicara Therapeutics Inc. (BCAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $13.98 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $13.15, a 36.98% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $9.60, a 135.29% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.08.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $14.40, a 93.03% increase from fiscal 2024.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $7.46, a 124.02% increase from fiscal 2023.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.33.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.98 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | $13.15 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | $14.40 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $11.66 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $12.16 10-Q · filed 2026-08-11 | ||||
| 2025-03-31 | $9.60 10-Q · filed 2026-05-11 | $4.13 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $7.46 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $6.99 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | $3.97 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | $4.08 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | $3.33 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $2.77 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |